Prevention of deep vein thrombosis in orthopedic surgery

European Journal of Medical Research

Volumn 9, Issue 3, 2004, Pages 112-118

  Eichinger, Sabine ^a   Kyrle, P A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Low molecular weight heparin; Orthopedic surgery; Thromboprophylaxis

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

HUMAN; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; REVIEW; VEIN THROMBOSIS;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOSIS;

EID: 4644304347     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. White RH, Gettner S, Newman JM, Trauner KB, Romano PS (2000) Predictors of Rehospitalization for Symptomatic- Venous Thromboembolism after Total Hip Arthroplasty. N Engl J Med 343: 1758-1764
2. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler (2001) Prevention of venous thromboembolism. Chest 119: 132S-175S
3. Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ, Jay RM, Neemeh J (1991) Prevention of deep vein thrombosis after elective hip surgery: A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 114: 545-551
4. The German Hip Arthroplasty trial (GHAT) Group (1992) Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg 111:110-120
5. Dechavanne M, Ville D, Berruyer M et al. (1989) Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted- dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis 1: 5-12
6. Norgren L, Toksvig-Larsen S, Magyar G, Lindstrand A, Albrechtsson U (1998) Prevention of deep vein thrombosis in knee arthroplasty. Preliminary results from a randomized controlled study of low molecular weight heparin vs foot pump compression. Int Angiol 17: 93-6
7. Blanchard J, Meuwly JY, Leyvraz PF, Miron MJ, Bounameaux H, Hoffmeyer P, Didier D, Schneider PA (1999) Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br 81: 654-9
8. Colwell CW Jr, Spiro TE, Trowbridge AA, Stephens JW, Gardiner GA Jr, Ritter MA (1995) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clin Orthop 321: 19-27
9. Fauno P, Suomalainen O, Rehnberg V, Hansen TB, Kroner K, Soimakallio S, Nielsen E (1994) Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin J Bone Joint Surg Am 76: 1814-1918
10. Monreal M, Lafoz E, Navarro A, Granero X, Caja V, Caceres E, Salvador R, Ruiz J (1989) A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. Trauma 29: 873-875
11. Moskovitz PA, Ellenberg SS, Feffer HL, Kenmore PI, Neviaser RJ, Rubin BE, Varma VM (1978) Lowdose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg Am 60: 1065-1070
12. Barsotti J, Gruel Y, Rosset P, et al. (1990) Comparative double-blind study of two dosage regimens of low-molecular weight heparin in elderly patients with a fracture of the neck of the femur. J Orthop Trauma 4: 371-375
13. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, et al. (1993) A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 329: 1370-1376
14. RD Heparin Arthroplasty Group (1994) RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am 76: 1174-1185
15. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R (2000) Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Int Med 160: 2199-207
16. Hamulyak K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA (1995) Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anti-coagulant Study Group. Thromb Haemost 74: 1428-1431
17. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Esperance B, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F (1996) Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 124: 619-626
18. Gerhart TN, Yett HS, Robertson LK, Lee MA, Smith M, Salzman EW (1991) Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial. J Bone Joint Surg 73: 494-502
19. Bauer KA (2003)New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. Chest 124: 364S-370S
20. Bauer KA, Eriksson BI, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Major Knee Surgery Study (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345: 1305-10
21. Eriksson BI, Bauer KA, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345: 1298-304
22. Lassen MR, Bauer KA, Eriksson BI, Turpie AG; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee (2002) Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359: 1715-20
23. Turpie AG, Bauer KA, Eriksson BI, Lassen MR; PENTATHALON 2000 Study Steering Committee (2002) Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359: 1721-6
24. Weltermann A, Kyrle PA, Eichinger S (2003) Novel anticoagulants for the prevention and treatment of venous thromboembolism. Wien Med Wochenschr 153: 426-33
25. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, Bylund R (2001) The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101: 171-81
26. Colwell CW, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Liebermann JR, Neubauer J, Whipple JP, Peters GR, Francis CW. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and enoxaparin to prevent venous thromboembolism (VTE) after total hip arthroplasty (THA). Blood 2001;98: 706a
27. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D; Melagatran for Thrombin inhibition in Orthopaedic surgery (2002) Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism. after total hip or knee replacement: the METHRO II randomised trial. Lancet 360: 1441-7
28. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M; METHRO III Study Group (2003) Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 89: 288-96
29. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilov S, Eskilson C, Andersson M, Freij A; EXPRESS Study Group (2003) The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 1. 2490-6
30. Strebel N, Prins M, Agnelli G et al. (2002) Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight-heparin in elective hip surgery? Arch Intern Med 162: 1451-1456
31. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Ghali WA, Butcher MS, Brant RF, Bergqvist D, Hamulyak K, Francis CW, Marder VJ, Raskob GE (2001) Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 161: 1952-1960
32. Bergqvist D, Benoni G, Biorgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G (1996) Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 335, 696-700
33. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y (1996) Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 348: 224-8
34. Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug JH, Arnesen H (1997) Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin) Thromb Haemost 77: 26-31
35. Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro HP, Andersen G, Petersen AO, Siem P, Horlyck E, Jensen BV, Thomsen PB, Hansen BR, Erin-Madsen J, Moller JC, Rotwitt L, Christensen F, Nielsen JB, Jorgensen PS, Paaske B, Torholm C, Hvidt P, Jensen NK, Nielsen AB, Appelquist E, Tialve E, et al. (1998) Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 89: 281-7
36. Eikelboom JW, Quinlan DJ, Douketis JD (2001) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358: 9-15
37. Hull RD, Pineo GF, Stein PD, Mah A.F, MacIsaac SM, Dahl OE, Butcher M, Brant RF, Ghali WA, Bergqvist D, Raskob GE (2001) Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 135: 858-69
38. Eriksson BI, Lassen MR; PENTasaccharide in HIp-FRActure Surgery Plus Investigators (2003) Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multi-center, randomized, placebo-controlled, double-blind study. Arch Intern Med 163: 1337-42
39. Prins MH, Hirsh J (1990) A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery: a critical review. Thromb Haemost 64: 497-500
40. Dalldorf PG, Perkins FM, Totterman S, Pellegrini VD Jr (1994) Deep venous thrombosis following total hip arthroplasty. Effects of prolonged postoperative epidural anesthesia. J Arthroplasty 9: 611-616
41. Sorenson RM, Pace NL (1992) Anesthetic techniques during surgical repair of femoral neck fractures. A meta-analysis. Anesthesiology 77: 1095-1104
42. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355: 1295-1302
43. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P (1997) A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337: 1329-1335
44. Gent M, Hirsh J, Ginsberg JS, Powers PJ, Levine MN, Geerts WH, Jay RM, Leclerc J, Neemeh JA, Turpie AG (1996) Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 93: 80-84
45. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G (1998) A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 338: 409-415